article thumbnail

Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic Cardiomyopathy

JAMA Cardiology

This cohort study evaluates the association of late gadolinium enhancement with sudden cardiac death or relevant associated events among patients younger than 21 years with hypertrophic cardiomyopathy.

article thumbnail

Obesity cardiomyopathy could contribute to sudden cardiac death: a Japanese epidemiological morphological study

Cardiovascular Diabetology

Background We aimed to clarify the existence and pathological features of obesity cardiomyopathy (OCM) in Japan using our series of autopsy cases. Approximately half the OCM cases were diagnosed with sudden cardiac death (SCD), with significant differences.

article thumbnail

Heart Vest Could Help Predict Sudden Cardiac Death Risk

DAIC

Image courtesy of UCL Institute of Cardiovascular Science / James Tye milla1cf Tue, 12/19/2023 - 18:19 December 19, 2023 — A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of sudden cardiac death , suggests a new study led by UCL researchers.

article thumbnail

PO-04-017 LIMITED PREDICTIVE ABILITY OF CURRENT GUIDELINES FOR SUDDEN CARDIAC DEATH RISK IN PEDIATRIC HYPERTROPHIC CARDIOMYOPATHY

HeartRhythm

Sudden cardiac death represents a significant mortality factor in hypertrophic cardiomyopathy (HCM). Nevertheless, the validation of the existing risk prediction model in the pediatric population remains insufficiently explored.

article thumbnail

The role of the molecular autopsy in sudden cardiac death in young individuals

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 23 January 2024; doi:10.1038/s41569-024-00989-0 A molecular autopsy is undertaken in cases of sudden cardiac death with no definitive cause found after conventional autopsy, with the aim of identifying a pathological genetic variant that could account for the death.

article thumbnail

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy

JAMA Cardiology

This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.

article thumbnail

PO-02-101 SILENT MYOCARDIAL INFARCTION AND DILATED CARDIOMYOPATHY AMONG COUNTYWIDE SUDDEN CARDIAC DEATHS

HeartRhythm

Sudden cardiac death (SCD) risk stratification is based on clinically recognized risk factors (RF), such as reduced left ventricular (LV) ejection fraction (EF), heart failure (HF), prior myocardial infarction (MI), and syncope. These RFs fail to capture the majority of SCDs.